PET imaging in Parkinson's disease

Current Medical Imaging Reviews

Volumn 3, Issue 4, 2007, Pages 233-241

  Dhawan, Vijay ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Dopamine Cell Implantation; Dopamine receptor density; Dopamine Transporter; Fluorodopa Uptake; Glial cell line derived neurotrophic factor

Indexed keywords

3 METHYLSPIPERONE C 11; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; FLUORODOPAMINE F 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; PLACEBO; RACLOPRIDE C 11; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ANTIBODY PRODUCTION; BLOOD BRAIN BARRIER; CELL TRANSPLANTATION; CLINICAL TRIAL; COMPUTER ANALYSIS; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSKINESIA; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE ANALYSIS; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; PALLIDOTOMY; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK REDUCTION; SIDE EFFECT; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING;

EID: 36949017930     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340507782446223     Document Type: Review

References (44)

1. Dhawan V, Eidelberg D. PET imaging in Parkinson's disease. Adv Clin Neurosci 2003; 13: 251-76.
2. Eidelberg D, Edwards C, Mentis M, Dhawan V, Moeller J. Movement disorders: Parkinson's disease. In: Mazziotta JC, Toga AW, Frackowiak R, editors. Brain Mapping: The Disorders. San Diego: Academic Press, 2000: 241-61.
3. Dhawan V, Eidelberg D. PET imaging in Parkinson's disease and other neurodegenerative disorders. In: Gilman S, editor. The neurobiology of disease. San Diego: Elsevier Academic Press, 2006: 821-8.
4. Brooks D, Ibanez V, Sawle G, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-92.
5. Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA. Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 1987; 7: 649-58.
6. Dhawan V, Kazumata K, Robeson W, et al. Quantitative brain PET: Comparison of 2D and 3D acquisitions on the GE Advance Scanner. Clin Pos Imag 1998; 1: 135-44.
7. Gjedde A, Reidi J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A 1991; 88: 2721-5.
8. Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FOOPA uptake in Parkinson's disease: raho method versus graphical approach. J Nucl Med 2002; 43: 1324-1330.
9. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F] fluorodeoxyglucose and [18F] fluorodopa positron emission tomographic studies. Mov Disord 1990; 5: 203-13.
10. Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 1996; 16: 854-63.
11. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol 1995; 38: 2604.
12. Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with Fluorine-18-FPCIT and PET. J Nucl Med 1998; 39: 1521-30.
13. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996; 47: 718-26.
14. Eidelberg D, Takikawa S, Dhawan V, et al. Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993; 13: 881-8.
15. Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006; 129: 1050-8.
16. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208-15.
17. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
18. Frey K, Koeppe R, Kilbourn M, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996; 40: 873-4.
19. Stoessl A, Ruth T. Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptive binding (including dopamine transporters, vesicle transporters, and post-synpatic receptor sites). Curr Opin Neurol 1998; 11: 327-33.
20. Eidelberg D, Moeller JR, Kazumata K, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997; 120: 1315-24.
21. Antonini A, Schwarz J, Oertel W, Pogarell O, Leenders K. Longterm changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and (11C] raclopride. Mov Disord 1997; 12: 33-8.
22. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994; 16: 255-62.
23. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995; 45: 1995-2004.
24. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999; 56: 179-87.
25. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 2005; 26: 912-21.
26. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical Parametric Maps in Functional Imaging: A General Linear Approach. Hum Brain Mapp 1995; 2: 189-210.
27. Ma Y, Eidelberg D. Functional Imaging of Cerebral Blood Flow and Glucose Metabolism in Parkinson's Disease and Huntington's Disease. Mol Imaging Biol 2007; 9: 223-233.
28. Moeller JR, Nakamura T, Mentis MJ, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999; 40: 1264-9.
29. Eckert T, Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2005; 2: 361-71.
30. Eidelberg D. Functional brain networks in movement disorders. Curr Opin Neurol 1998; 11: 319-26.
31. Eckert T, Van Laere K, Tang C, et al. Quantification of PD-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007; 34: 496-501.
32. Spetsieris P, Ma Y, Dhawan V, Moeller JR, Eidelberg D. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: Medical Imaging 2006; 6144: 61445M1-12.
33. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130: 1834-46.
34. Feigin A, Lewis D, Huang C, Dhawan V, Eidelberg D. Parkinsonian patients without evidence of a dopaminergic deficit: an F-DOPA and FDG PET study. Neurology 2005; 64 (suppl 1): A234.
35. Kazumata K, Antonini A, Dhawan V, et al. Preoperative indicators of clinical outcome following stereotaxic pallidotomy. Neurology 1997; 49: 1083-90.
36. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006; 129(Pt 10): 2667-78.
37. Ma Y, Dhawan V, Freed C, Falm S, Eidelberg D. PET and embryonic dopamine cell transplantation in Parkinson's disease. In: Broderick PA, Rabni DN, Kolodny EH, editors. Bioimaging in neurodegeneration. New Jersey: Humana Press, 2005: 45-58.
38. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-9.
39. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001; 50: 181-7.
40. Ma Y, Feigin A, Dhawan V, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52: 628-34.
41. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
42. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurtrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
43. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-95.
44. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-66.